Human Embryonic Stem Cells and Their Differentiated Derivatives Are Less Susceptible to Immune Rejection Than Adult Cells
The DOI matches its Crossref record; 48 of the 49 references it cites were found in a registry or an index.
Abstract
Differentiated cell types derived from human embryonic stem cells (hESCs) may serve in the future to treat various human diseases. A crucial step toward their successful clinical application is to examine the immune response that might be launched against them after transplantation. We used two experimental platforms to examine the in vivo leukocyte response toward hESCs. First, immunocompetent and immunodeficient mouse strains were used to identify T cells as the major component that causes xenorejection of hESCs. Second, mice that were conditioned to carry peripheral blood leukocytes from human origin were used to test the human leukocyte alloresponse toward undifferentiated and differentiated hESCs. Using this model, we have detected only a minute immune response toward undifferentiated as well as differentiated hESCs over the course of 1 month, although control adult grafts were repeatedly infiltrated with lymphocytes and destroyed. Our data show that the cells evade immune destruction due to a low immunostimulatory potential. Nevertheless, a human cytotoxic T lymphocyte clone that was specifically prepared to recognize two hESC lines could lyse the cells after major histocompatibility complex class I (MHC-I) induction. Although MHC-I levels in hESCs are sufficient for rejection by cytotoxic T cells, our data suggest that the immunostimulatory capacity of the cells is very low. Thus, immunosuppressive regimens for hESC-based therapeutics could be highly reduced compared with conventional organ transplantation because direct allorejection processes of hESCs and their derivatives are considerably weaker.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although most of the pluripotent stem cells have low HLA expression [93], iPSC derivatives can trigger an immune response.”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [93]
Citations
Cites
Embryonic Stem Cell Lines Derived from Human Blastocysts
Thomson, J. A., Itskovitz-Eldor, J., Shapiro, S. S., Waknitz, M. A., Swiergiel, J. J., Marshall, V. S., & Jones, J. M. (1998) · Science · doi:10.1126/science.282.5391.1145 · Cited by 15,926
Embryonic stem cell lines from human blastocysts: somatic differentiation in vitro
Reubinoff, B. E., Pera, M. F., Fong, C.-Y., Trounson, A., & Bongso, A. (2000) · Nature Biotechnology · doi:10.1038/74447 · Cited by 2,706
In vitro differentiation of transplantable neural precursors from human embryonic stem cells
Zhang, S.-C., Wernig, M., Duncan, I. D., Brüstle, O., & Thomson, J. A. (2001) · Nature Biotechnology · doi:10.1038/nbt1201-1129 · Cited by 1,912
Kehat, I., Kenyagin‐Karsenti, D., Snir, M., Segev, H., Amit, M., Gepstein, A., Livne, E., Binah, O., Itskovitz‐Eldor, J., & Gepstein, L. (2001) · Journal of Clinical Investigation · doi:10.1172/jci12131 · Cited by 1,814
Sharpe, A. H., & Freeman, G. J. (2002) · Nature Reviews Immunology · doi:10.1038/nri727 · Cited by 1,712
Kehat, I., Kenyagin‐Karsenti, D., Snir, M., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci200112131 · Cited by 1,536
Itskovitz-Eldor, J., Schuldiner, M., Karsenti, D., Eden, A., Yanuka, O., Amit, M., Soreq, H., & Benvenisty, N. (2000) · Molecular Medicine · doi:10.1007/bf03401776 · Cited by 1,500
Self-citationPrognostically Useful Gene-Expression Profiles in Acute Myeloid Leukemia
Valk, P. J. M., Verhaak, R. G. W., Beijen, M. A., Erpelinck, C. A. J., van Doorn-Khosrovani, S. B. V. W., Boer, J. M., Beverloo, H. B., Moorhouse, M. J., van der Spek, P. J., Löwenberg, B., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040465 · Cited by 1,370
Schuldiner, M., Yanuka, O., Itskovitz-Eldor, J., Melton, D. A., & Benvenisty, N. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.21.11307 · Cited by 1,134
Self-citationNeural progenitors from human embryonic stem cells
Reubinoff, B. E., Itsykson, P., Turetsky, T., Pera, M. F., Reinhartz, E., Itzik, A., & Ben-Hur, T. (2001) · Nature Biotechnology · doi:10.1038/nbt1201-1134 · Cited by 1,119
Cited by
Embryonic stem cell trials for macular degeneration: a preliminary report
Schwartz, S. D., Hubschman, J.-P., Heilwell, G., Franco-Cardenas, V., Pan, C. K., Ostrick, R. M., Mickunas, E., Gay, R., Klimanskaya, I., & Lanza, R. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60028-2 · Cited by 1,409
Risk factors in the development of stem cell therapy
Herberts, C. A., Kwa, M. S., & Hermsen, H. P. (2011) · Journal of Translational Medicine · doi:10.1186/1479-5876-9-29 · Cited by 753
“Both ESC-derived cells [87-89] and especially MSCs [81,90,91] have been reported to be immune-privileged and have a low immunogenic potential.”
BackgroundHentze, H., Soong, P. L., Wang, S. T., Phillips, B. W., Putti, T. C., & Dunn, N. R. (2009) · Stem Cell Research · doi:10.1016/j.scr.2009.02.002 · Cited by 501
“A study by Drukker et al. established that T cells play a crucial role in the xenorejec-tion of implanted hESCs by comparing undifferentiated hESCs in immunocompetent versus immunodeficient mice (Drukker et al., 2006).”
Carr, A.-J., Vugler, A. A., Hikita, S. T., Lawrence, J. M., Gias, C., Chen, L. L., Buchholz, D. E., Ahmado, A., Semo, M., Smart, M. J. K., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0008152 · Cited by 413
“immune responses[60–62].”
Biomaterials in cardiac tissue engineering: Ten years of research survey
Chen, Q.-Z., Harding, S. E., Ali, N. N., Lyon, A. R., & Boccaccini, A. R. (2008) · Materials Science and Engineering: R: Reports · doi:10.1016/j.mser.2007.08.001 · Cited by 382
Prospects for Stem Cell-Based Therapy
Daley, G. Q., & Scadden, D. T. (2008) · Cell · doi:10.1016/j.cell.2008.02.009 · Cited by 302
“Some data suggest that human ESCs may be less susceptible to immune attack either because of low-level expression of class I HLA molecules or active suppression of the immune response through uncertain mechanisms (Drukker et al., 2006; Li et al., 2004).”
BackgroundImmunosuppressive therapy mitigates immunological rejection of human embryonic stem cell xenografts
Swijnenburg, R.-J., Schrepfer, S., Govaert, J. A., Cao, F., Ransohoff, K., Sheikh, A. Y., Haddad, M., Connolly, A. J., Davis, M. M., Robbins, R. C., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805802105 · Cited by 297
Scalable Stirred-Suspension Bioreactor Culture of Human Pluripotent Stem Cells
Kehoe, D. E., Jing, D., Lock, L. T., & Tzanakakis, E. S. (2010) · Tissue Engineering Part A · doi:10.1089/ten.tea.2009.0454 · Cited by 264
“119 Human ESCs exhibit low immunogenicity, 120,121 but the changes in immunocompatibility brought about by their culture should be further elucidated.”
Schwartz, S. D., Tan, G., Hosseini, H., & Nagiel, A. (2016) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.15-18681 · Cited by 245
Chang, C., Yen, M., Chen, Y., Chien, C., Huang, H., Bai, C., & Yen, B. L. (2006) · STEM CELLS · doi:10.1634/stemcells.2006-0071 · Cited by 251
Toward the development of a global induced pluripotent stem cell library
Turner, M., Leslie, S., Martin, N. G., Peschanski, M., Rao, M., Taylor, C. J., Trounson, A., Turner, D., Yamanaka, S., & Wilmut, I. (2013) · Cell stem cell · doi:10.1016/j.stem.2013.08.003 · Cited by 245
“Despite the fact that pluripotent stem cell lines and cells derived therefrom appear to demonstrate low expression of HLA antigens (Drukker et al. 2006), it is clear that differentiated cells do generate an allogeneic response as seen by T cell proliferation and cellular apoptosis against 3…”
BackgroundStem Cell Imaging: From Bench to Bedside
Nguyen, P. K., Riegler, J., & Wu, J. C. (2014) · Cell Stem Cell · doi:10.1016/j.stem.2014.03.009 · Cited by 234
“…molecules, as well as their expression of immune-modulating molecules (Abdullah et al., 2007; Koch et al., 2008; Magliocca et al., 2006), have been found to elicit a donor-specific immune response when transplanted into immune competent mice (Drukker et al., 2006; Swijnenburg et al., 2008a).”
Retinal stem cell transplantation: Balancing safety and potential
Singh, M. S., Park, S. S., Albini, T. A., Canto-Soler, M. V., Klassen, H., MacLaren, R. E., Takahashi, M., Nagiel, A., Schwartz, S. D., & Bharti, K. (2020) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2019.100779 · Cited by 225
“Modern stem cell technologies have yielded clinical grade cellular therapies that are under investigation for retinal degenerations from both human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) (Drukker et al., 2006; Odorico et al., 2001; Polak and Bishop, 2006; Takahashi et al., 2007; Yu et…”
Effects of cell number on teratoma formation by human embryonic stem cells
Lee, A. S., Tang, C., Cao, F., Xie, X., van der Bogt, K., Hwang, A., Connolly, A. J., Robbins, R. C., & Wu, J. C. (2009) · Cell Cycle · doi:10.4161/cc.8.16.9353 · Cited by 225
Li, Z., Suzuki, Y., Huang, M., Cao, F., Xie, X., Connolly, A. J., Yang, P. C., & Wu, J. C. (2008) · Stem Cells · doi:10.1634/stemcells.2007-0843 · Cited by 214
Derivation of a Xeno‐Free Human Embryonic Stem Cell Line
Ellerström, C., Strehl, R., Moya, K., Andersson, K., Bergh, C., Lundin, K., Hyllner, J., & Semb, H. (2006) · STEM CELLS · doi:10.1634/stemcells.2006-0130 · Cited by 209
Chen, X., Aledia, A. S., Popson, S. A., Him, L., Hughes, C. C. W., & George, S. C. (2010) · Tissue Engineering Part A · doi:10.1089/ten.tea.2009.0491 · Cited by 204
“16 Alternatively, there is significant evidence demonstrating the angiogenic potential Departments of 1 Biomedical Engineering and 2 Molecular Biology and Biochemistry, 3 The Edwards Lifesciences Center for Advanced Cardiovascular Technology, and 4 Department of Chemical Engineering and Material…”
Cell therapy and the safety of embryonic stem cell-derived grafts
Hentze, H., Graichen, R., & Colman, A. (2007) · Trends in Biotechnology · doi:10.1016/j.tibtech.2006.10.010 · Cited by 197
Cho, S.-W., Moon, S.-H., Lee, S.-H., Kang, S.-W., Kim, J., Lim, J. M., Kim, H.-S., Kim, B.-S., & Chung, H. M. (2007) · Circulation · doi:10.1161/circulationaha.106.687038 · Cited by 196
Karussis, D., Kassis, I., Kurkalli, B. G. S., & Slavin, S. (2008) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2007.05.005 · Cited by 193
“However, recent data have indicated that ESCs may exhibit immune-privileged properties[20,21], and escape rejection through immunotolerance.”
BackgroundRobertson, N. J., Brook, F. A., Gardner, R. L., Cobbold, S. P., Waldmann, H., & Fairchild, P. J. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710265105 · Cited by 183
Amniotic Membrane and Amniotic Fluid-Derived Cells: Potential Tools for Regenerative Medicine?
Parolini, O., Soncini, M., Evangelista, M., & Schmidt, D. (2009) · Regenerative Medicine · doi:10.2217/17460751.4.2.275 · Cited by 176
Stem cells for the treatment of spinal cord injury
Coutts, M., & Keirstead, H. S. (2008) · Experimental Neurology · doi:10.1016/j.expneurol.2007.09.002 · Cited by 177
Nakajima, F., Tokunaga, K., & Nakatsuji, N. (2007) · Stem Cells · doi:10.1634/stemcells.2006-0566 · Cited by 168
The Immunogenicity and Immune Tolerance of Pluripotent Stem Cell Derivatives
Liu, X., Li, W., Fu, X., & Xu, Y. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00645 · Cited by 164
“Second, while ESCs do not directly activate allogeneic T cell through the interaction between allogeneic MHC molecules and TCR, ESCs express immunogenic antigens such as MHC Class I molecules and Oct4 that can indirectly activate T cells through antigen presenting cells (22, 23, 26).”
BackgroundTissue engineering with nano-fibrous scaffolds
Smith, L. A., Liu, X., & Ma, P. X. (2008) · Soft Matter · doi:10.1039/b807088c · Cited by 165
Immunogenicity of Pluripotent Stem Cells and Their Derivatives
de Almeida, P. E., Ransohoff, J. D., Nahid, A., & Wu, J. C. (2013) · Circulation Research · doi:10.1161/circresaha.111.249243 · Cited by 170
“Rejection of undifferentiated human ES cells has been suggested to be largely T-cell–mediated, whereas NK cells and B cells play only a minor role.(17) However, in a rat model, NK cells have been implicated in the killing of undifferentiated mouse ES cells.”
BackgroundInfluentialSurvival and maturation of human embryonic stem cell-derived cardiomyocytes in rat hearts
Dai, W., Field, L. J., Rubart, M., Reuter, S., Hale, S. L., Zweigerdt, R., Graichen, R. E., Kay, G. L., Jyrala, A. J., Colman, A., et al. (2007) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2007.07.001 · Cited by 158
“Finally, several previous cross-species transplantation studies suggested that ESC-derived cells might evade immune surveillance [18,19,20,21].”
ResultHuman hepatocyte transplantation: state of the art
Fitzpatrick, E., Mitry, R. R., & Dhawan, A. (2009) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2009.02152.x · Cited by 155
Cell-based transplantation strategies to promote plasticity following spinal cord injury
Ruff, C. A., Wilcox, J. T., & Fehlings, M. G. (2011) · Experimental Neurology · doi:10.1016/j.expneurol.2011.02.010 · Cited by 158
“As with any allogenic transplantation, patient immunosupression will be necessary, and there is evidence that immunosuppressive regimes, in conjunction with ESC transplant, may be insufficient to thwart a continued immune response (Drukker et al., 2006; Grinnemo et al., 2006; Preynat-Seauve et al., 2009).”
Hartman, M. E., Dai, D.-F., & Laflamme, M. A. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.05.004 · Cited by 138
“While it is possible that PSC-based therapies will evoke a less robust immune reaction than wholeorgan transplantation (particularly if the injectate is devoid of antigen-presenting cells such as endothelial cells) [176, 177], the successful clinical translation of these cells will undoubtedly require dealing with the…”
BackgroundChiavegato, A., Bollini, S., Pozzobon, M., Callegari, A., Gasparotto, L., Taiani, J., Piccoli, M., Lenzini, E., Gerosa, G., Vendramin, I., et al. (2006) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2006.12.008 · Cited by 147
Immunological considerations for embryonic and induced pluripotent stem cell banking
Taylor, C. J., Bolton, E. M., & Bradley, J. A. (2011) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2011.0030 · Cited by 139
Zhu, K., Wu, Q., Ni, C., Zhang, P., Zhong, Z., Wu, Y. R., Wang, Y., Xu, Y., Kong, M., Cheng, H., et al. (2018) · Circulation Research · doi:10.1161/circresaha.117.311578 · Cited by 149
Immunological Applications of Stem Cells in Type 1 Diabetes
Fiorina, P., Voltarelli, J., & Zavazava, N. (2011) · Endocrine Reviews · doi:10.1210/er.2011-0008 · Cited by 135
“Another study reported only a minor immuneresponse against human ESCs in mice conditioned to carry human leukocytes (39), confirming the lack of expression of MHC class II, as well as low expression of costimulatory molecules and MHC class I (39).”
BackgroundMoving Stem Cells to the Clinic: Potential and Limitations for Brain Repair
Steinbeck, J. A., & Studer, L. (2015) · Neuron · doi:10.1016/j.neuron.2015.03.002 · Cited by 133
Gropp, M., Shilo, V., Vainer, G. W., Gov, M., Gil, Y., Khaner, H., Matzrafi, L., Idelson, M., Kopolovic, J., Zak, N. B., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0045532 · Cited by 137
“Immune deficient NOD/SCID mice were used in our assay since they tolerate hESC grafts and support the development of teratoma tumors [2,15].”
Reyes, J. H., O’Shea, K. S., Wys, N. L., Velkey, J. M., Prieskorn, D. M., Wesolowski, K., Miller, J. M., & Altschuler, R. A. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.0563-08.2008 · Cited by 136
SOX17 enables immune evasion of early colorectal adenomas and cancers
Goto, N., Westcott, P. M. K., Goto, S., Imada, S., Taylor, M. S., Eng, G., Braverman, J., Deshpande, V., Jacks, T., Agudo, J., et al. (2024) · Nature · doi:10.1038/s41586-024-07135-3 · Cited by 116
Suárez-Álvarez, B., Rodríguez, R. M. A., Calvanese, V., Blanco-Gelaz, M. Á., Suhr, S. T., Ortega, F., Otero, J., Cibelli, J. B., Moore, H. D. M., Fraga, M. F., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010192 · Cited by 123
“Some soluble factors, such as TGF-b [21] and FasL [3] had been proposed to inhibit immune responses by ESCs.”
BackgroundStem cell therapy for cardiac disease
Bernstein, H. S., & Srivastava, D. (2012) · Pediatric Research · doi:10.1038/pr.2011.61 · Cited by 134
“This observation suggests that immunosuppressive regimens for hESC-based therapeutics may not need to be as rigorous as those for conventional organ transplantation (66).”
Rosen, C., Shezen, E., Aronovich, A., Klionsky, Y. Z., Yaakov, Y., Assayag, M., Biton, I. E., Tal, O., Shakhar, G., Ben‐Hur, H., et al. (2015) · Nature Medicine · doi:10.1038/nm.3889 · Cited by 119
Self-citationDressel, R., Schindehütte, J., Kuhlmann, T., Elsner, L., Novota, P., Baier, P. C., Schillert, A., Bickeböller, H., Herrmann, T., Trenkwalder, C., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002622 · Cited by 119
“It is well known that mouse [8,10,15–18] and human ES cells [19,20] can give rise to teratomas when injected into immunodeficient hosts.”
BackgroundCell-based therapeutic strategies for replacement and preservation in retinal degenerative diseases
Jones, M. K., Lü, B., Girman, S., & Wang, S. (2017) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2017.01.004 · Cited by 125
Naserian, S., Abdelgawad, M. E., Bakshloo, M. A., Ha, G., Arouche, N., Cohen, J. L., Salomon, B. L., & Uzan, G. (2020) · Cell Communication and Signaling · doi:10.1186/s12964-020-00564-3 · Cited by 110
Zhang, K., Pang, K., & Wu, X. (2014) · Stem Cells and Development · doi:10.1089/scd.2013.0510 · Cited by 106
Surface marker antigens in the characterization of human embryonic stem cells
Wright, A. J., & Andrews, P. W. (2009) · Stem Cell Research · doi:10.1016/j.scr.2009.04.001 · Cited by 109
Endothelial potential of human embryonic stem cells
Levenberg, S., Zoldan, J., Basevitch, Y., & Langer, R. (2007) · Blood · doi:10.1182/blood-2006-08-019190 · Cited by 110
Human embryonic stem cells are immunogenic in allogeneic and xenogeneic settings
Grinnemo, K., Kumagai‐Braesch, M., Månsson‐Broberg, A., Skottman, H., Hao, X., Siddiqui, A. J., Andersson, A., Strömberg, A., Lahesmaa, R., Hovatta, O., et al. (2006) · Reproductive BioMedicine Online · doi:10.1016/s1472-6483(10)60663-3 · Cited by 102
Stem-cell approaches for kidney repair: choosing the right cells
Sagrinati, C., Ronconi, E., Lazzeri, E., Lasagni, L., & Romagnani, P. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2008.05.005 · Cited by 102
Potential and Limitation of HLA-Based Banking of Human Pluripotent Stem Cells for Cell Therapy
de Rham, C., & Villard, J. (2014) · Journal of Immunology Research · doi:10.1155/2014/518135 · Cited by 96
“The killing mechanism of CD8+Tcells is mediated by the presentation of the antigen to the T-cell receptor, and NK cells kill the target cells expressing low level or no HLA-I.”
BackgroundInfluentialStem/Progenitor Cell Sources of Insulin-Producing Cells for the Treatment of Diabetes
Lock, L. T., & Tzanakakis, E. S. (2007) · Tissue Engineering · doi:10.1089/ten.2007.0047 · Cited by 98
HLA-Matching Potential of an Established Human Embryonic Stem Cell Bank in China
Lin, G., Xie, Y., OuYang, Q., Qian, X., Xie, P., Zhou, X., Xiong, B., Tan, Y., Li, W., Deng, L., et al. (2009) · Cell stem cell · doi:10.1016/j.stem.2009.10.009 · Cited by 97
Pluripotent Stem Cells: Immune to the Immune System?
Pearl, J. I., Kean, L. S., Davis, M. M., & Wu, J. C. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3005090 · Cited by 101
Human embryonic stem cells: Current technologies and emerging industrial applications
Améen, C., Strehl, R., Björquist, P., Lindahl, A. H., Hyllner, J., & Sartipy, P. (2007) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2007.06.012 · Cited by 104
“In addition, hES cells have been found to e less susceptible to immune rejection than adult cells [184].”
BackgroundSzot, G. L., Yadav, M., Lang, J., KROON, E. J., Kerr, J. M., Kadoya, K., Brandon, E. P., Baetge, E. E., Bour-Jordan, H., & Bluestone, J. A. (2014) · Cell stem cell · doi:10.1016/j.stem.2014.12.001 · Cited by 98
“Of note, earlier studies had concluded that hESCs benefited from an immune-privileged status in vitro and in vivo (Drukker et al., 2006; Li et al., 2004).”
BackgroundWu, D. C., Boyd, A. S., & Wood, K. J. (2008) · Stem Cells · doi:10.1634/stemcells.2008-0078 · Cited by 95
Immunogenicity and Engraftment of Mouse Embryonic Stem Cells in Allogeneic Recipients
Bonde, S., & Zavazava, N. (2006) · Stem Cells · doi:10.1634/stemcells.2006-0022 · Cited by 90
Totipotency and lineage segregation in the human embryo
Paepe, C. D., Krivega, M., Cauffman, G., Geens, M., & de Velde, H. V. (2014) · Molecular Human Reproduction · doi:10.1093/molehr/gau027 · Cited by 97
Li, Y., Zeng, H., Xu, R., Liu, B., & Li, Z. (2009) · Stem Cells · doi:10.1002/stem.234 · Cited by 88
Anderson, A. J., Haus, D. L., Hooshmand, M. J., Perez, H. D., Sontag, C. J., & Cummings, B. J. (2011) · Regenerative Medicine · doi:10.2217/rme.11.22 · Cited by 85
Addressing Stem Cell Therapeutic Approaches in Pathobiology of Diabetes and Its Complications
Peng, B., Dubey, N. K., Mishra, V. K., Tsai, F.-C., Dubey, R., Deng, W., & Wei, H.-J. (2018) · Journal of Diabetes Research · doi:10.1155/2018/7806435 · Cited by 89
Tissue engineering: current status and future perspectives
Chandra, P. K., Söker, S., & Atala, A. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-818422-6.00004-6 · Cited by 109
Immunogenicity of human embryonic stem cells
Grinnemo, K., Sylvén, C., Hovatta, O., Dellgren, G., & Corbascio, M. (2007) · Cell and Tissue Research · doi:10.1007/s00441-007-0486-3 · Cited by 87
“The in vitro data (Drukker et al. 2006) indicating that HESC loaded with influenza virus type A peptide are not recognised by human cytotoxic T cells merely supports the theory that HESC are poor antigen-presenting cells.”
BackgroundInfluentialOcular Immune Privilege and Ocular Melanoma: Parallel Universes or Immunological Plagiarism?
Niederkorn, J. Y. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00148 · Cited by 86
“…IMMUNOREGULATORY PROCESSES THAT SUSTAIN IMMUNE PRIVILEGE In addition to soluble and cell membrane-bound molecules that dampen immune-mediated inflammation, immune privileged sites are designed to promote the generation of dynamic immunoregulatory processes that down-regulate adaptive immune…”
BackgroundConcise Review: Immune Recognition of Induced Pluripotent Stem Cells
Boyd, A. S., Rodrigues, N. P., Lui, K. O., Fu, X., & Xu, Y. (2012) · Stem Cells · doi:10.1002/stem.1066 · Cited by 82
Ding, D.-C., Chou, H.-L., Chang, Y.-H., Hung, W.-T., Liu, H.-W., & Chu, T.-Y. (2016) · Cell Transplantation · doi:10.3727/096368915x688182 · Cited by 72
“As with fetal MSCs or embryonic stem cells, these extra-embryonic fetal MSCs are also immunologically naive (9,12).”
BackgroundKang, H. M., Kim, J.-Y., Park, S., Kim, J., Kim, H., Kim, K. S., Lee, J. E., Seo, S. I., Kang, S. G., Lee, J. E., et al. (2009) · Stem Cells · doi:10.1002/stem.127 · Cited by 74
Kawaguchi, T., Tsukiyama, T., Kimura, K., Matsuyama, S., Minami, N., Yamada, M., & Imai, H. (2015) · PLoS ONE · doi:10.1371/journal.pone.0135403 · Cited by 79
“The difficulty of developing mature teratomas from naïve-like human iPSCs has been described previously [6, 45, 46], and the specific strain of immunodeficient mouse affects teratoma formation [47].”
BackgroundKramer, A. S., Harvey, A. R., Plant, G. W., & Hodgetts, S. I. (2013) · Cell Transplantation · doi:10.3727/096368912x655208 · Cited by 79
Stem Cells for Heart Cell Therapies
Jing, D., Parikh, A., Canty, J. M., & Tzanakakis, E. S. (2008) · Tissue Engineering Part B: Reviews · doi:10.1089/ten.teb.2008.0262 · Cited by 73
Mesenchymal cells for skeletal tissue engineering
Slater, B. J., Kwan, M. D., Gupta, D. M., Panetta, N. J., & Longaker, M. T. (2008) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.8.7.885 · Cited by 78
“There has been some data to suggest that human ESCs are less susceptible to immune rejection than adult cells due to decreased expression of class I HLA molecules or another unknown mechanism [19] .”
BackgroundFord, E., Pearlman, J., Ruan, T., Manion, J., Waller, M. A., Neely, G. G., & Caron, L. (2020) · Cells · doi:10.3390/cells9112517 · Cited by 74
The stem cell marker nestin predicts poor prognosis in human melanoma
Piras, F. (2009) · Oncology Reports · doi:10.3892/or_00000601 · Cited by 77
“…extent of metastatic involvement (41) In our study, decreased survival time of patients with advanced normal stem cells is their low immunogenicity (42,43) that, although it represents an advantage for human stem cell therapies, on the other hand it could present a problem for immunotherapy (44).”
Embryonic stem cells and retinal repair
Vugler, A., Lawrence, J. M., Walsh, J., Carr, A. F., Gias, C., Semo, M., Ahmado, A., da Cruz, L., Andrews, P. W., & Coffey, P. J. (2007) · Mechanisms of Development · doi:10.1016/j.mod.2007.08.002 · Cited by 80
“Gene array data suggests that immunological maturity is a late event in gestation and embryonic stem cells do not reach this point (Drukker et al., 2006).”
Tan, Y., Ooi, S., & Wang, L. (2013) · Current Stem Cell Research & Therapy · doi:10.2174/1574888x113086660068 · Cited by 78
“Formation of an "optimal peptide" bond allows MHC class I to be released and exported to the cell surface for presentation to T cells [24-26] (Fig.”
Immunological properties of human embryonic stem cell-derived oligodendrocyte progenitor cells
Okamura, R. M., LEBKOWSKI, J. S., Au, M., Priest, C. A., Denham, J., & Majumdar, A. S. (2007) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2007.09.030 · Cited by 76
“Furthermore, in an animal model of the human immune system, human peripheral blood leukocytes did not reject engrafted hESCs (Drukker et al., 2006).”
BackgroundInfluentialIdeguchi, M., Shinoyama, M., Gomi, M. N., Hayashi, H., Hashimoto, N., & Takahashi, J. B. (2008) · Journal of Neuroscience Research · doi:10.1002/jnr.21652 · Cited by 71
“, 2002) and have a poor costimulatory capacity even after differentiation and INF-g treatment (Drukker et al., 2006).”
BackgroundCell therapy for heart disease after 15 years: Unmet expectations
Nigro, P., Bassetti, B., Cavallotti, L., Catto, V., Carbucicchio, C., & Pompilio, G. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.02.015 · Cited by 74
A Pure Population of Ectodermal Cells Derived from Human Embryonic Stem Cells
Aberdam, E., Barak, E., Rouleau, M., de LaForest, S., Berrih-Aknin, S., Suter, D. M., Krause, K.-H., Amit, M., Itskovitz-Eldor, J., & Aberdam, D. (2008) · Stem Cells · doi:10.1634/stemcells.2007-0588 · Cited by 70
The immune response of stem cells in subretinal transplantation
Xian, B., & Huang, B. Q. (2015) · Stem Cell Research & Therapy · doi:10.1186/s13287-015-0167-1 · Cited by 75
“Second, ESCs lack co-stimulatory molecules, such as CD80 and CD86 [38].”
BackgroundHLA-G Expression in Human Embryonic Stem Cells and Preimplantation Embryos
Verloes, A., de Velde, H. V., LeMaoult, J., Mateizel, I., Cauffman, G., Horn, P. A., Carosella, E. D., Devroey, P., Waele, M. D., Rebmann, V., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1001081 · Cited by 70
“(20), who showed that hESC (undifferentiated and differentiated) fail to stimulate proliferation of alloreactive T cells, and transplantation of these cells into human PBMC-reconstituted mice gave no rejection (17).”
BackgroundFraga, A. M., Sukoyan, M. A., Rajan, P., Braga, D. P. D. A. F., Iaconelli, A., Franco, J. G., Jr., Borges, E., & Pereira, L. V. (2010) · Cell Transplantation · doi:10.3727/096368910x522261 · Cited by 70
Clonal Analysis of Human Embryonic Stem Cell Differentiation into Teratomas
Blum, B., & Benvenisty, N. (2007) · Stem Cells · doi:10.1634/stemcells.2007-0073 · Cited by 70
Self-citationPluripotent Stem Cells for Retinal Tissue Engineering: Current Status and Future Prospects
Singh, R. K., Cuzzani, O., Binette, F., Sternberg, H., West, M. D., & Nasonkin, I. O. (2018) · Stem Cell Reviews and Reports · doi:10.1007/s12015-018-9802-4 · Cited by 70
Stem cell therapy for retinal disease
Tibbetts, M. D., Samuel, M. A., Chang, T. S., & Ho, A. C. (2012) · Current Opinion in Ophthalmology · doi:10.1097/icu.0b013e328352407d · Cited by 68
Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy
Nicholson, M. W., Ting, C.-Y., Chan, D. Z. H., Cheng, Y.-C., Lee, Y.-C., Hsu, C.-C., Huang, C.-Y., & Hsieh, P. C. H. (2022) · Cells · doi:10.3390/cells11111853 · Cited by 65
“Although most of the pluripotent stem cells have low HLA expression [93], iPSC derivatives can trigger an immune response.”
BackgroundYang, J., Lam, D. H., Goh, S. S., Lee, E. X., Zhao, Y. H., Tay, F. C., Chen, C., Du, S., Balasundaram, G., Shahbazi, M., et al. (2012) · Stem Cells · doi:10.1002/stem.1051 · Cited by 66
RetractedShi, L., Li, W., Liu, Y., Chen, Z., Hui, Y., Hao, P., Xu, X., Zhang, S., Feng, H., Zhang, B., et al. (2020) · Stem Cells · doi:10.1002/stem.3269 · Cited by 62
Zimmermann, A., Preynat-Seauve, O., Tiercy, J.-M., Krause, K.-H., & Villard, J. (2012) · Stem Cells and Development · doi:10.1089/scd.2012.0088 · Cited by 62
“This hypothesis seemed confirmed by the very low expression of HLA class I antigens (which appeared only weakly increased through differentiation), and by the lack of expression of HLA class II [14,15].”
Human Embryonic Stem Cells Suppress T Cell Responses via Arginase I-Dependent Mechanism
Yachimovich‐Cohen, N., Even‐Ram, S., Shufaro, Y., Rachmilewitz, J., & Reubinoff, B. E. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0804261 · Cited by 63
Zhu, J., Zhang, K., Sun, Y., Gao, X., Li, Y., Chen, Z., & Wu, X. (2013) · Tissue Engineering Part A · doi:10.1089/ten.tea.2013.0097 · Cited by 63
“22,23 Hence, hESCs, which possessed the inexhaustible proliferation capacity and the satisfactory differentiation ability, might provide an infinite cell source for constructing tissue-engineering grafts.”
Walia, B., Satija, N. K., Tripathi, R. P., & Gangenahalli, G. U. (2011) · Stem Cell Reviews and Reports · doi:10.1007/s12015-011-9279-x · Cited by 68
Embryonic Stem Cells: Overcoming the Immunological Barriers to Cell Replacement Therapy
Lui, K. O., Waldmann, H., & Fairchild, P. J. (2009) · Current Stem Cell Research & Therapy · doi:10.2174/157488809787169093 · Cited by 63
Immunogenicity of embryonic stem cell-derived progenitors after transplantation
English, K., & Wood, K. J. (2010) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0b013e3283424faa · Cited by 67
The potential use of stem cells in multiple sclerosis: An overview of the preclinical experience
Karussis, D. M., & Kassis, I. (2008) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2008.02.008 · Cited by 64
“However, recent data have indicated that ESCs ay exhibit immune-privileged properties [31,32], and may scape rejection through immunotolerance.”
Human embryonic stem cells and cardiac repair
Zhu, W., Hauch, K. D., Xu, C., & Laflamme, M. A. (2008) · Transplantation Reviews · doi:10.1016/j.trre.2008.05.005 · Cited by 70
Converting human pluripotent stem cells into β-cells: recent advances and future challenges
Mayhew, C. N., & Wells, J. M. (2010) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0b013e3283337e1c · Cited by 59
Cardiac Regeneration using Human Embryonic Stem Cells: Producing Cells for Future Therapy
Wong, S. S. Y., & Bernstein, H. S. (2010) · Regenerative Medicine · doi:10.2217/rme.10.52 · Cited by 60
The Potential for Stem Cell Therapy in Diabetes
Meier, J. J., Bhushan, A., & Butler, P. C. (2006) · Pediatric Research · doi:10.1203/01.pdr.0000206857.38581.49 · Cited by 76
“Theoretically, ES cells can be manipulated ex vivo to induce immune-compatibility with the intended recipient (90,91) avoiding the need for immunosuppression and its attendant side effects (44,45).”
Metadata
- Authors
- Drukker, M., Katchman, H., Katz, G., Even-Tov Friedman, S., Shezen, E., Hornstein, E., Mandelboim, O., Reisner, Y., & Benvenisty, N.
- Affiliations
- Hebrew University of Jerusalem (IL)
- Weizmann Institute of Science (IL)
- Department of Immunology, Weizmann Institute of Science, Rehovot, Israel
- Corresponding author
- Drukker, Micha
- Venue
- Stem Cells
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-08-18
- Volume
- 24
- Issue
- 2
- Pages
- 221-229
- ISSN
- 1066-5099 (ISSN-L)
- 1549-4918
- OpenAlex
- W2006712783
- Cited by
- 402
- References
- 49
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 6 · 2023: 6 · 2022: 6 · 2021: 9 · 2020: 11 · 2019: 12 · 2018: 16 · 2017: 15 · 2016: 12 · 2015: 21 · 2014: 19 · 2013: 30 · 2012: 34
- FWCI
- 14.48
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- Stem Cells (publishedVersion)
- PubMed (publishedVersion)
- Site cant be reached (submittedVersion)
- Funders
- Israel Science Foundation
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
- Health Sciences › Medicine › Surgery › Xenotransplantation and immune response
- Health Sciences › Medicine › Transplantation › Organ and Tissue Transplantation Research
- Keywords
- human embryonic stem cells, immune rejection, xenotransplantation, allorejection, T cell response, cytotoxic T lymphocytes, MHC class I, immunodeficient mice, immunocompetent mice, cell therapy, immunosuppression
- MeSH terms
- Animals, Cell Differentiation, Embryo, Mammalian, Graft Rejection, Humans, Immunocompetence, Membrane Glycoproteins, Mice, Inbred Strains, Mice, Mutant Strains, Stem Cells, T-Lymphocytes, Cytotoxic, Transplantation, Heterologous, T-Lymphocyte Subsets, Mice, SCID, Gene Expression Profiling, Stem Cell Transplantation, Tumor Necrosis Factors, Mice, Fas Ligand Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.